中天宏信(00994.HK)成立合營從事電商零售及線上線下諮詢服務
中天宏信(00994.HK)公布,與浙江順聯及浙江順聯的一名高級管理人員成立合營企業,主要從事自家品牌商品的電商零售業務,及為電商公司提供線上線下諮詢服務業務。合營企業由公司全資附屬公司深圳中天宏信、浙江順聯及浙江順聯的一名高級管理人員分別擁有51%、39%及10%。因此,合營企業為公司的附屬公司。
公司指,成立合營企業是為善用中國電商行業的巨大潛力及浙江順聯在中國的聲譽,以向電商公司提供採購服務及相關線上及線下諮詢服務。
目前,合營企業已與中和亞健康服務中心訂立戰略合作協議,建立網上平台以銷售保健產品及提供與保健有關的培訓計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.